Eradication of Chemotherapy-resistant CD44+ Human Ovarian Cancer Stem Cells in Mice by Intraperitoneal Administration of Clostridium Perfringens Enterotoxin

Overview

Journal Cancer

Publisher Wiley

Specialty Oncology

Date 2011 Jun 22

PMID 21692061

Citations 42

Authors

Francesca Casagrande

Emiliano Cocco

Stefania Bellone

Christine E Richter

Marta Bellone

Paola Todeschini

Eric Siegel

Joyce Varughese

Dan Arin-Silasi

Masoud Azodi

Thomas J Rutherford

Sergio Pecorelli

Peter E Schwartz

Alessandro D Santin

Affiliations

Soon will be listed here.

Abstract

Background: Emerging evidence has suggested that the capability to sustain tumor formation, growth, and chemotherapy resistance in ovarian as well as other human malignancies exclusively resides in a small proportion of tumor cells termed cancer stem cells. During the characterization of CD44(+) ovarian cancer stem cells, we found a high expression of the genes encoding for claudin-4. Because this tight junction protein is the natural high-affinity receptor for Clostridium perfringens enterotoxin (CPE), we have extensively investigated the sensitivity of ovarian cancer stem cells to CPE treatment in vitro and in vivo.

Methods: Real-time polymerase chain reaction and flow cytometry were used to evaluate claudin-3/-4 expression in ovarian cancer stem cells. Small interfering RNA knockdown experiments and MTS assays were used to evaluate CPE-induced cytotoxicity against ovarian cancer stem cell lines in vitro. C.B-17/SCID mice harboring ovarian cancer stem cell xenografts were used to evaluate CPE therapeutic activity in vivo.

Results: CD44(+) ovarian cancer stem cells expressed claudin-4 gene at significantly higher levels than matched autologous CD44(-) ovarian cancer cells, and regardless of their higher resistance to chemotherapeutic agents died within 1 hour after exposure to 1.0 μg/mL of CPE in vitro. Conversely, small-interfering RNA-mediated knockdown of claudin-3/-4 expression in CD44(+) cancer stem cells significantly protected cancer stem cells from CPE-induced cytotoxicity. Importantly, multiple intraperitoneal administrations of sublethal doses of CPE in mice harboring xenografts of chemotherapy-resistant CD44(+) ovarian cancer stem cells had a significant inhibitory effect on tumor progression leading to the cure and/or long-term survival of all treated animals (ie, 100% reduction in tumor burden in 50% of treated mice; P < .0001).

Conclusions: CPE may represent an unconventional, potentially highly effective strategy to eradicate chemotherapy-resistant cancer stem cells.

Citing Articles

Nanomaterial-assisted oncolytic bacteria in solid tumor diagnosis and therapeutics.

Zeng X, Chen Q, Chen T Bioeng Transl Med. 2024; 9(4):e10672.

PMID: 39036084 PMC: 11256190. DOI: 10.1002/btm2.10672.

The Role of Cancer Stem Cell Markers in Ovarian Cancer.

Fraszczak K, Barczynski B Cancers (Basel). 2024; 16(1).

PMID: 38201468 PMC: 10778113. DOI: 10.3390/cancers16010040.

Targeting ovarian cancer stem cells: a new way out.

Ma H, Tian T, Cui Z Stem Cell Res Ther. 2023; 14(1):28.

PMID: 36788591 PMC: 9926632. DOI: 10.1186/s13287-023-03244-4.

Ovarian cancer stem cells: Critical roles in anti-tumor immunity.

Ding J, Zhang Y, Che Y Front Genet. 2022; 13:998220.

PMID: 36437919 PMC: 9685611. DOI: 10.3389/fgene.2022.998220.

Loss of Claudin-4 Reduces DNA Damage Repair and Increases Sensitivity to PARP Inhibitors.

Yamamoto T, Webb P, Davis D, Baumgartner H, Woodruff E, Guntupalli S Mol Cancer Ther. 2022; 21(4):647-657.

PMID: 35373300 PMC: 8988515. DOI: 10.1158/1535-7163.MCT-21-0827.

References

McClane B . An overview of Clostridium perfringens enterotoxin. Toxicon. 1996; 34(11-12):1335-43. DOI: 10.1016/s0041-0101(96)00101-8. View

Stewart J, White J, Yan X, Collins S, Drescher C, Urban N . Proteins associated with Cisplatin resistance in ovarian cancer cells identified by quantitative proteomic technology and integrated with mRNA expression levels. Mol Cell Proteomics. 2005; 5(3):433-43. DOI: 10.1074/mcp.M500140-MCP200. View

Dean M, Fojo T, Bates S . Tumour stem cells and drug resistance. Nat Rev Cancer. 2005; 5(4):275-84. DOI: 10.1038/nrc1590. View

Curley M, Therrien V, Cummings C, Sergent P, Koulouris C, Friel A . CD133 expression defines a tumor initiating cell population in primary human ovarian cancer. Stem Cells. 2009; 27(12):2875-83. DOI: 10.1002/stem.236. View

Katahira J, Inoue N, Horiguchi Y, Matsuda M, Sugimoto N . Molecular cloning and functional characterization of the receptor for Clostridium perfringens enterotoxin. J Cell Biol. 1997; 136(6):1239-47. PMC: 2132509. DOI: 10.1083/jcb.136.6.1239. View

Bapat S, Mali A, Koppikar C, Kurrey N . Stem and progenitor-like cells contribute to the aggressive behavior of human epithelial ovarian cancer. Cancer Res. 2005; 65(8):3025-9. DOI: 10.1158/0008-5472.CAN-04-3931. View

Katahira J, Sugiyama H, Inoue N, Horiguchi Y, Matsuda M, Sugimoto N . Clostridium perfringens enterotoxin utilizes two structurally related membrane proteins as functional receptors in vivo. J Biol Chem. 1997; 272(42):26652-8. DOI: 10.1074/jbc.272.42.26652. View

Deng S, Yang X, Lassus H, Liang S, Kaur S, Ye Q . Distinct expression levels and patterns of stem cell marker, aldehyde dehydrogenase isoform 1 (ALDH1), in human epithelial cancers. PLoS One. 2010; 5(4):e10277. PMC: 2858084. DOI: 10.1371/journal.pone.0010277. View

Reya T, Morrison S, Clarke M, Weissman I . Stem cells, cancer, and cancer stem cells. Nature. 2001; 414(6859):105-11. DOI: 10.1038/35102167. View

10.

Landen Jr C, Goodman B, Katre A, Steg A, Nick A, Stone R . Targeting aldehyde dehydrogenase cancer stem cells in ovarian cancer. Mol Cancer Ther. 2010; 9(12):3186-99. PMC: 3005138. DOI: 10.1158/1535-7163.MCT-10-0563. View

11.

Alvero A, Fu H, Holmberg J, Visintin I, Mor L, Marquina C . Stem-like ovarian cancer cells can serve as tumor vascular progenitors. Stem Cells. 2009; 27(10):2405-13. PMC: 2783765. DOI: 10.1002/stem.191. View

12.

Yin G, Chen R, Alvero A, Fu H, Holmberg J, Glackin C . TWISTing stemness, inflammation and proliferation of epithelial ovarian cancer cells through MIR199A2/214. Oncogene. 2010; 29(24):3545-53. PMC: 2889129. DOI: 10.1038/onc.2010.111. View

13.

Michl P, Buchholz M, Rolke M, Kunsch S, Lohr M, McClane B . Claudin-4: a new target for pancreatic cancer treatment using Clostridium perfringens enterotoxin. Gastroenterology. 2001; 121(3):678-84. DOI: 10.1053/gast.2001.27124. View

14.

Santin A, Cane S, Bellone S, Palmieri M, Siegel E, Thomas M . Treatment of chemotherapy-resistant human ovarian cancer xenografts in C.B-17/SCID mice by intraperitoneal administration of Clostridium perfringens enterotoxin. Cancer Res. 2005; 65(10):4334-42. DOI: 10.1158/0008-5472.CAN-04-3472. View

15.

Mueller M, Hermann P, Heeschen C . Cancer stem cells as new therapeutic target to prevent tumour progression and metastasis. Front Biosci (Elite Ed). 2009; 2(2):602-13. DOI: 10.2741/e117. View

16.

Jemal A, Siegel R, Ward E, Hao Y, Xu J, Thun M . Cancer statistics, 2009. CA Cancer J Clin. 2009; 59(4):225-49. DOI: 10.3322/caac.20006. View

17.

Alberts D, Markman M, Armstrong D, Rothenberg M, Muggia F, Howell S . Intraperitoneal therapy for stage III ovarian cancer: a therapy whose time has come!. J Clin Oncol. 2002; 20(19):3944-6. DOI: 10.1200/JCO.2002.20.19.3944. View

18.

Zhang S, Balch C, Chan M, Lai H, Matei D, Schilder J . Identification and characterization of ovarian cancer-initiating cells from primary human tumors. Cancer Res. 2008; 68(11):4311-20. PMC: 2553722. DOI: 10.1158/0008-5472.CAN-08-0364. View

19.

Long H, Crean C, Lee W, Cummings O, Gabig T . Expression of Clostridium perfringens enterotoxin receptors claudin-3 and claudin-4 in prostate cancer epithelium. Cancer Res. 2001; 61(21):7878-81. View

20.

Kamsteeg M, Rutherford T, Sapi E, Hanczaruk B, Shahabi S, Flick M . Phenoxodiol--an isoflavone analog--induces apoptosis in chemoresistant ovarian cancer cells. Oncogene. 2003; 22(17):2611-20. DOI: 10.1038/sj.onc.1206422. View